Total Payments
$305,747
2024 Payments
$57,447
Companies
58
Transactions
1,226
Medicare Patients
7,579
Medicare Billing
$1.0M
Payment Breakdown by Category
Other$259,633 (84.9%)
Food & Beverage$37,690 (12.3%)
Travel$6,976 (2.3%)
Research$1,282 (0.4%)
Education$165.58 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $259,633 | 93 | 84.9% |
| Food and Beverage | $37,690 | 1,102 | 12.3% |
| Travel and Lodging | $6,976 | 15 | 2.3% |
| Unspecified | $1,282 | 4 | 0.4% |
| Education | $165.58 | 12 | 0.1% |
Payments by Type
General
$304,464
1,222 transactions
Research
$1,282
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $227,134 | 357 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $50,098 | 260 | $0 (2024) |
| Allergan, Inc. | $5,481 | 18 | $0 (2020) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $3,666 | 138 | $0 (2024) |
| Insmed, Inc. | $1,995 | 27 | $0 (2024) |
| ViiV Healthcare Company | $1,600 | 1 | $0 (2019) |
| GENZYME CORPORATION | $1,488 | 40 | $0 (2024) |
| Actelion Pharmaceuticals US, Inc. | $1,233 | 39 | $0 (2024) |
| Grifols USA, LLC | $1,219 | 40 | $0 (2024) |
| United Therapeutics Corporation | $999.86 | 18 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $57,447 | 181 | GlaxoSmithKline, LLC. ($31,017) |
| 2023 | $69,913 | 175 | GlaxoSmithKline, LLC. ($55,738) |
| 2022 | $70,333 | 217 | GlaxoSmithKline, LLC. ($60,680) |
| 2021 | $49,599 | 180 | GlaxoSmithKline, LLC. ($39,902) |
| 2020 | $37,312 | 148 | GlaxoSmithKline, LLC. ($31,342) |
| 2019 | $13,125 | 153 | GlaxoSmithKline, LLC. ($7,770) |
| 2018 | $3,337 | 103 | AstraZeneca Pharmaceuticals LP ($569.91) |
| 2017 | $4,683 | 69 | Allergan Inc. ($2,236) |
All Payment Transactions
1,226 individual payment records from CMS Open Payments — Page 1 of 50
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/17/2024 | Amgen Inc. | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $121.08 | General |
| Category: Inflammation | ||||||
| 12/12/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $22.34 | General |
| Category: RESPIRATORY | ||||||
| 12/11/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $18.24 | General |
| Category: Respiratory | ||||||
| 12/09/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,800.00 | General |
| Category: Respiratory | ||||||
| 12/06/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $21.14 | General |
| Category: Respiratory | ||||||
| 12/04/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Travel and Lodging | In-kind items and services | $760.65 | General |
| Category: Respiratory | ||||||
| 12/04/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $91.81 | General |
| Category: Respiratory | ||||||
| 11/27/2024 | Amgen Inc. | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $24.48 | General |
| Category: Inflammation | ||||||
| 11/26/2024 | GENZYME CORPORATION | DUPIXENT (Biological), DUPIXENT | Food and Beverage | In-kind items and services | $113.85 | General |
| Category: Immunology | ||||||
| 11/25/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,850.00 | General |
| Category: Respiratory | ||||||
| 11/20/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $116.43 | General |
| Category: Respiratory | ||||||
| 11/19/2024 | GENZYME CORPORATION | DUPIXENT (Biological), DUPIXENT | Food and Beverage | In-kind items and services | $88.37 | General |
| Category: Immunology | ||||||
| 11/14/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $14.85 | General |
| Category: Respiratory | ||||||
| 11/13/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,850.00 | General |
| Category: Respiratory | ||||||
| 11/12/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $118.61 | General |
| Category: IMMUNOLOGY | ||||||
| 11/11/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $22.22 | General |
| Category: Respiratory | ||||||
| 11/07/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $21.75 | General |
| Category: Respiratory | ||||||
| 11/07/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $13.11 | General |
| Category: RESPIRATORY | ||||||
| 11/05/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $82.72 | General |
| Category: Respiratory | ||||||
| 10/30/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $29.85 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 10/29/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $118.92 | General |
| Category: IMMUNOLOGY | ||||||
| 10/29/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $24.61 | General |
| Category: IMMUNOLOGY | ||||||
| 10/28/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: IMMUNOLOGY | ||||||
| 10/23/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $27.86 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 1,913 | 2,900 | $548,860 | $216,110 |
| 2022 | 15 | 1,630 | 8,129 | $823,493 | $333,257 |
| 2021 | 17 | 2,014 | 3,103 | $615,712 | $242,631 |
| 2020 | 16 | 2,022 | 3,069 | $648,771 | $233,880 |
Total Patients
7,579
Total Services
17,201
Medicare Billing
$1.0M
Procedure Codes
63
All Medicare Procedures & Services
63 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 318 | 730 | $167,900 | $69,427 | 41.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 287 | 588 | $126,420 | $54,208 | 42.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 72 | 72 | $29,808 | $12,459 | 41.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 86 | 87 | $33,756 | $12,023 | 35.6% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 242 | 276 | $29,808 | $11,602 | 38.9% |
| 94726 | Test to determine lung volumes using sensors | Office | 2023 | 249 | 284 | $30,956 | $11,008 | 35.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 125 | 162 | $23,490 | $10,759 | 45.8% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 39 | 41 | $23,288 | $7,017 | 30.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 38 | 43 | $12,384 | $5,740 | 46.3% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 256 | 296 | $21,608 | $5,683 | 26.3% |
| 71250 | Ct scan of chest without contrast | Office | 2023 | 47 | 53 | $15,370 | $5,501 | 35.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 62 | 81 | $11,590 | $5,166 | 44.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 23 | 23 | $7,682 | $2,795 | 36.4% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 52 | 64 | $4,800 | $1,659 | 34.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 17 | 100 | $10,000 | $1,066 | 10.7% |
| J2182 | Injection, mepolizumab, 1 mg | Office | 2022 | 11 | 5,405 | $270,000 | $124,597 | 46.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 370 | 1,040 | $239,200 | $84,392 | 35.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 244 | 478 | $102,770 | $44,841 | 43.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 137 | 141 | $54,708 | $22,212 | 40.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 176 | 254 | $36,830 | $15,703 | 42.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 55 | 55 | $22,770 | $8,515 | 37.4% |
| 71250 | Ct scan of chest without contrast | Office | 2022 | 52 | 61 | $17,690 | $6,288 | 35.5% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2022 | 118 | 125 | $13,500 | $5,548 | 41.1% |
| 94726 | Test to determine lung volumes using sensors | Office | 2022 | 122 | 130 | $14,170 | $5,245 | 37.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 37 | 37 | $12,358 | $4,337 | 35.1% |
About Dr. Fred Umeh, MD
Dr. Fred Umeh, MD is a Pulmonary Disease healthcare provider based in Kissimmee, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1114995842.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Fred Umeh, MD has received a total of $305,747 in payments from pharmaceutical and medical device companies, with $57,447 received in 2024. These payments were reported across 1,226 transactions from 58 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($259,633).
As a Medicare-enrolled provider, Umeh has provided services to 7,579 Medicare beneficiaries, totaling 17,201 services with total Medicare billing of $1.0M. Data is available for 4 years (2020–2023), covering 63 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Other Specialties Critical Care Medicine
- Location Kissimmee, FL
- Active Since 03/09/2006
- Last Updated 05/12/2021
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1114995842
Products in Payments
- NUCALA (Biological) $99,710
- TRELEGY ELLIPTA (Drug) $63,172
- BREZTRI (Drug) $27,057
- FASENRA (Biological) $18,657
- ANORO (Drug) $7,676
- AVYCAZ (Drug) $5,381
- ANORO ELLIPTA (Drug) $3,731
- DUPIXENT (Biological) $1,880
- Arikayce (Drug) $1,802
- OFEV (Drug) $1,396
- BREZTRI AEROSPHERE (Drug) $970.37
- UPTRAVI (Drug) $809.56
- Prolastin-C Liquid (Biological) $759.15
- TEZSPIRE (Biological) $755.74
- FASENRA (Drug) $712.85
- Adempas (Drug) $582.38
- SPIRIVA RESPIMAT (Drug) $513.07
- SYMBICORT (Drug) $490.35
- XYWAV (Drug) $470.47
- (8874) inCourage (Device) $438.59
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Kissimmee
Fortune Alabi, Md, MD
Pulmonary Disease — Payments: $593,712
Pulmonary Disease $593,712
Mr. Donald Elton, M.d, M.D
Pulmonary Disease — Payments: $19,986
Pulmonary Disease $19,986
Dr. Arelis Cordero-Gomez, Md, MD
Pulmonary Disease — Payments: $16,168
Pulmonary Disease $16,168
Dr. James Lucio, M.d, M.D
Pulmonary Disease — Payments: $9,576
Pulmonary Disease $9,576
Dr. Rhoderick Nazario, M.d, M.D
Pulmonary Disease — Payments: $8,454
Pulmonary Disease $8,454
Miguel Ortiz-Bonilla, Md, MD
Pulmonary Disease — Payments: $7,246
Pulmonary Disease $7,246